Allogene Therapeutics Status update
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello. Thank you for standing by, and welcome to Allogene Therapeutics conference call. After the speaker's presentation, there will be a question-and-answer session. At this time, all participants are in a listen-only mode. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be aware that today's conference call is being recorded. I would now like to turn the call over to Christine Cassiano, Chief Corporate Affairs and Brand Strategy Officer. Ms. Cassiano, please go ahead.
Thank you, operator, and welcome everyone to Allogene's webinar, focused on our first clinical findings from the phase I RESOLUTION trial with ALLO-329. Earlier this morning, Allogene issued a press release that provided an overview of this data. The poster presentation from ACR Convergence will occur after this call. The press release, presentation, and poster associated with this data will be available on our website. Today, we are joined by Dr. Zachary Roberts, President and Chief Executive Officer, and Dr. Vivek Nagaraja of Mayo Clinic Arizona, both of whom will be available for questions following today's presentation. During today's call, we will be making certain forward-looking statements, including statements regarding the development of ALLO-329, its potential safety, efficacy, tolerability, and durability, and its potential to provide clinical benefit in autoimmune diseases.
These statements may also address the potential to reduce or eliminate lymphodepleting chemotherapy, the relationship between B-cell depletion and clinical response, and the significance of findings across different dose levels and conditioning approaches. We may also discuss continued dose escalation, future clinical data updates, and plans for advancing the RESOLUTION program. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change. A description of potential risks can be found in our press release and latest SEC disclosure documents. You are cautioned not to place undue reliance on these forward-looking statements, and Allogene disclaims any obligation to update these statements. I'll now turn the call over to Zach.
Thanks, Christine. Good morning, everybody. Today marks an important milestone for ALLO-329, which is, of course, our first clinical and translational data from the ongoing RESOLUTION study. From the start, our objective has been to develop an allogeneic CAR T specifically for autoimmune disease, in which we prioritize safety, clinical benefit, and aim to reduce the treatment burden for this group of patients. On today's call, we will be joined by Dr. Vivek Nagaraja, who is Chair of Rheumatology at Mayo Clinic Arizona, as well as an investigator on the study. He brings firsthand experience treating patients in RESOLUTION and deep experience in scleroderma. As I discussed on our quarterly call, when we began thinking about our approach to allogeneic CAR T in 2024, we really started to think from the patients and then work backwards.
We asked, what was preventing patients from benefiting from CAR T, and how could we use the distinct advantages of an off-the-shelf platform to overcome those barriers? That thinking became particularly important in autoimmune disease, where these patients often live with chronic conditions for many years, making the balance between therapeutic benefit, treatment risk, and burden fundamentally different from that in oncology. At the end of the day, we did not want to simply repurpose an oncology CAR T. We knew that we needed a different product to treat a different group of patients, so we developed a therapy that met the needs of patients specifically with autoimmune disease. Of course, when treating these patients, safety is at the center of all of the decisions that we have been making. That philosophy has shaped the design of the ALLO-329 product, as well as the RESOLUTION trial itself.
As we were developing the ALLO-329 product, we made three deliberate choices that would make this a differentiated product. First, of course, it is off the shelf. So scalable manufacturing available for all the patients in this very large group of diseases and with high unmet need. It is a dual-targeting CAR, the first ever to target both CD19 and CD70, and particularly inclusion of that CD70 as our Dagger technology. So ALLO-329 with this design targets both CD19-positive B cells as well as CD70-positive activated T cells, both of which are believed to contribute to autoimmune disease. Additionally, because that Dagger, the CD70 molecule, is designed to address immune rejection of allogeneic CAR T cells, we believe that this molecule, the CD70 CAR, can actually help reduce or even eliminate the need for chemotherapy that is traditionally required before treatment with CAR T cells.
Ultimately, the objective of this program is to deliver meaningful clinical benefit without introducing unnecessary treatment and complexity, treatment risk and complexity, and to create a therapy that could be more practical for physicians and patients to embrace. Coming to the study itself, we deliberately designed the study to evaluate multiple dose levels of CAR T. So five are featured in the design of the study. Critically, we also created a parallel dose escalation pathway across three different lymphodepletion approaches: no lymphodepletion at all, Cytoxan alone, and Flu/Cy. You will see the data organized around these three lymphodepletion approaches. The design of this trial allows us to ask an important question. First, how much of the treatment of benefit, and safety for that matter, comes from the CAR T itself? Secondly, how much lymphodepletion is actually needed, if any?
On slide seven, we feature a little bit of data around the Dagger technology itself. Traditionally, lymphodepleting chemotherapy has played an important role in CAR T, in part specifically in AlloCAR Ts, in suppressing the patient's immune system to allow the infused cells to expand and persist. But that chemotherapy, of course, always brings toxicity, no matter what. Whether it is Flu/Cy, whether it is Cytoxan alone, it adds to the overall toxicity burden of CAR T cells in autoimmune disease, but also in oncology. In the worst case, these combination chemotherapy regimens can lead to prolonged immunosuppressions of both B cells and T cells, and thereby adding to the overall burden of CAR T, particularly in the context of opportunistic infections. The Dagger molecule was designed to address a fundamental challenge in allogeneic CAR T.
Can we use this product design feature to reject the CAR T cells by the patient's own immune system, thereby doing the job of the lymphodepletion? That is the goal of the Dagger. The bit of data that is shown on the screen right now is modeled in mice, in where we have taken mice in which we mimicked a lymphodepleted state versus a non-lymphodepleted state, and then treated these mice with either a CD19 CAR or an ALLO-329 CD19/CD70 CAR. In the case of the mice that were mimicked to have lymphodepletion, we saw great expansion and persistence of the CD19 CAR, and some, but somewhat less, expansion and persistence of ALLO-329.
Paradoxically, in a non-lymphodepleted mouse, we saw rapid rejection of CD19 CAR, but actually 10- to 20-fold better expansion and persistence of ALLO-329, thereby indicating that the potency of an allo response in mice, as we have seen in our clinical program with ALLO-316, actually engenders better cellular kinetics. This is the biology that is baked into the design of ALLO-329. The question is now whether that advantage can translate into meaningful clinical activity with less chemotherapy, and therefore a potentially more favorable treatment experience for patients and their physicians. Moving on to slide eight now. With that background, let's turn to what we are actually learning as first patients treated with ALLO-329. Overall, there are three things that I want to focus on. First, of course, as the phase I first in humans, the emerging safety profile. Then the clinical improvements we are seeing in patients with scleroderma.
Finally, what can we learn from the translational data that we have developed so far? I will have with me today Dr. Nagaraja, who I will turn to from time to time to help provide some additional explanation or color on what the findings that I am sharing mean. Okay, so slide 10. Sorry, slide nine. This is a familiar cartoon to many. This is a first-in-human phase I dose escalation trial evaluating ALLO-329 in scleroderma, lupus, and inflammatory myositis. The design of the study allows us to evaluate different cell doses and conditioning strategies while beginning to distinguish the effects of CAR T distinct from the effects caused by the chemotherapy itself. The data that we are presenting today represent only the first two dose levels with no LD and FC-based LD, and the first three dose levels for Cy alone, with enrollments and dose escalation continuing.
Overall, we are still pretty early in the dose escalation of the RESOLUTION study, and already we are beginning to see some interesting findings, both on the safety and on the efficacy side, that allow us to begin to answer some important questions about how this treatment could be further optimized and then widely deployed. On slide 10, this is the CONSORT diagram of what we will be discussing today. Overall, by the time of the data cutoff, we had 18 patients who had been enrolled and infused with ALLO-329. This represents the safety analysis set, so we will be covering safety on all 18 of these patients. Then you can see in today's presentation, this being a first-come-first-serve basket study, most of the patients came in with diffuse cutaneous scleroderma. So very little involvement by lung, mostly skin findings in these patients.
You can see those broken down across the three lymphodepletion regimens, no LD, Cy alone, and Flu/Cy. Notably, the others that you see enrolled there that will not be featured for efficacy today will be considered for future presentations. The scleroderma cohort, given the fact that we were starting with 10, had a good mix of LD regimens and cell doses, which is allowing us to shed a bit of light into the role of lymphodepletion as well as the dose escalation of the cells. On slide 11, we are getting into the data now. The early safety data shows a favorable tolerability profile. Of course, this being a phase I, this is the primary endpoint of this trial at this point, is the rate of dose-limiting toxicities.
You can see there across the top line, we do not have any dose-limiting toxicities observed to date. Around these 18 patients, we have also seen no IEC-HS, no ICANS, no graft-versus-host disease, and no grade 3 or higher CRS. We did have four cases of CRS, all grade 1 or 2. Importantly, no patients in the no lymphodepletion cohorts experienced treatment-emergent adverse events greater than grade 2. Importantly, if you look at that column, no LD, we saw no infections of any kind or prolonged cytopenias in the patients who received no chemotherapy-based lymphodepletion. Again, highlighting the value of de-intensifying the lymphodepletion regimen given to these patients with autoimmune diseases. We recognize that these are early safety results, but so far, so good.
We are very pleased with the safety profile observed to date, and particularly given our deliberate efforts to minimize the toxicity burden, and particularly in light of some of the news events from the summer indicating rates of high-grade toxicities that have led to study pauses with other products. Now I am going to turn to Dr. Nagaraja and ask, Dr. Nagaraja, when you see this safety profile, what stands out to you?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
